Animal Or Plant Cell Patents (Class 424/93.7)
  • Patent number: 11041144
    Abstract: The present invention is directed towards methods for producing cell and tissue compositions suitable for therapeutic applications to a mammal in need of a therapeutic cell or tissue treatment. In particular, the invention is directed towards a method of culturing cells for use in therapy, which method comprises (i) culturing a sample of cells in a first cell culture medium and (ii) prior to harvesting cells for use in therapy culturing the cells in a second cell culture medium.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: June 22, 2021
    Assignee: ISOPOGEN PTY LTD
    Inventor: Marian June Sturm
  • Patent number: 11041011
    Abstract: T cell receptors that specifically recognize hAFP158 and methods of their use are provided.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: June 22, 2021
    Assignees: Augusta University Research Institute, Inc., National Institutes of Health (NIH), U.S. Dept. of Health And Human Services (DHHS), U.S. Government NIH Division of Extramural Inventionsl and Technology Resources (DEITR)
    Inventors: Yukai He, Wei Zhu, Esteban Celis, Yibing Peng, Lan Wang
  • Patent number: 11040019
    Abstract: Methods are disclosed for treating and/or preventing retinal degeneration is a subject. In some embodiments, the method includes administering to the subject a therapeutically effective amount of a selective estrogen receptor modulator (SERM) to treat the retinal degeneration in the subject. In other embodiments, the SERM is administered orally. In some examples, the SERM is tamoxifen, afimoxifene, raloxifene, bazedoxifene, arzoxifene, desmethylarzoxifene, or a salt or derivative thereof, or combinations thereof.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: June 22, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Wenxin Ma, Lian Zhao, Xu Wang, Wai T. Wong
  • Patent number: 11033586
    Abstract: The present invention provides a method of producing a cell sheet comprising a retinal pigment epithelial cell layer and a vascular forming cell layer composed of stem cells having vascular formation ability or blood vessel constituting cells, comprising a step of laminating the retinal pigment epithelial cell layer and the vascular forming cell layer, and a cell sheet obtained by said method. Furthermore, the present invention provides a cell sheet for transplantation, comprising a cell layer formed with retinal pigment epithelial cells obtained by inducing differentiation of stem cells or progenitor cells ex vivo, a basement membrane secreted from said cells, and a vascular forming cell layer composed of stem cells having vascular formation ability or blood vessel constituting cells.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: June 15, 2021
    Assignee: RIKEN
    Inventors: Masayo Takahashi, Hiroyuki Kamao
  • Patent number: 11027047
    Abstract: Provided herein according to some embodiments is a biocompatible scaffold comprising stem cells (e.g., a pliable scaffold) suitable for intracavity administration after surgical removal of a tumor, wherein the scaffold allows the stem cells to migrate away from the scaffold and towards a cancerous or damaged tissue, wherein the stem cells are loaded with a therapeutic agent and/or a reporter molecule. Methods of forming the scaffold, and methods of use thereof, are also provided.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 8, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Shawn D. Hingtgen, Julio Rodriguez Bago, Matthew G. Ewend, Karen J. Giroux, Raluca Dumitru
  • Patent number: 11020436
    Abstract: The present invention generally relates to a stem cell concentrate isolated from a mammalian vascularized adipose tissue, biopharmaceuticals containing such concentrate and use thereof in therapies for treating diseases in mammals.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: June 1, 2021
    Assignee: REGENERA—MEDICINA VETERINÁRIA AVANÇADA LTDA.
    Inventors: Alexandre Kerkis, Cristiane Valverde Wenceslau, Michele Andrade De Barros, João Flávio Panattoni Martins
  • Patent number: 11013670
    Abstract: The present invention relates to a hyaluronic acid microstructure having excellent solubility characteristics. More specifically, the present invention relates to a biodegradable microstructure comprising crosslinked hyaluronic acid and having excellent solubility characteristics during skin penetration. When the microstructure of the present invention is penetrated into the skin, the solubility characteristics in the skin are excellent, the dissolution rate in the skin can be easily controlled according to the content ratio of the crosslinked hyaluronic acid, and, while effective ingredients provided on the microstructure can be stably delivered into the skin, the release rate of the provided effective ingredients can be easily controlled, and thus the present invention can be used as a transdermal delivery system for pharmacologically active materials or skin improvement materials.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: May 25, 2021
    Assignee: ENDODERMA CO., LTD.
    Inventors: Jae Soo Kim, Soon Chang Kwon, Sang Jin Park
  • Patent number: 11016091
    Abstract: A method for identifying T-cell epitopes which can be used to elicit T cells targeting cells capable of regenerating cancers is disclosed. The method identifies T-cell epitopes with a high curative potential, high potency and high probability of T cell recognition (HP). The method includes: (i) identifying high curative potential tumor protein target i.e., identifying HP-TP; (ii) identifying peptide sequences within the protein sequence of an HP-TP that have a high probability of eliciting T cell killing; and (iii) qualifying the sequence specificity based on the fold difference between the specific target and non-targets. The identified T-cell epitopes include a core sequence of 9 amino acids homologous to a sequence expressed within a qualified HP-TP. The T-cell epitopes can be used in a method for reprograming T cells to selectively attack tumor cells capable of perpetuating a tumor and treating patients, for example, cancer patients.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: May 25, 2021
    Assignee: VERIK BIO, INC.
    Inventors: Nancy Parenteau, Joseph Laning, Janet Young
  • Patent number: 11007230
    Abstract: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by degeneration of motor neurons in the spinal cord and brain. Increasing evidence shows autoimmune mechanisms likely promote disease progression. Human umbilical cord blood (hUCB) derived plasma is rich in cytokines and growth factors that are required for growth and survival of cells during hematopoiesis. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: May 18, 2021
    Assignees: University of South Florida, Saneron CCEL Therapeutics, Inc.
    Inventors: Svitlana Garbuzova-Davis, Jared Carl Ehrhart, Paul R. Sanberg
  • Patent number: 11007221
    Abstract: This invention relates to acellular-based therapies for decreasing the level of regulatory T cells (Treg) and/or increasing the level of pro-inflammatory T cells (Th17) to favor immune stimulation. To provide these therapeutic effects, an allogeneic leukocyte population is contacted with another leukocyte population and the acellular components produced are isolated. The leukocyte populations are contacted so as to allow pro-inflammatory allo-recognition. Acellular-based preparations and processes for achieving therapy are also provided.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: May 18, 2021
    Assignee: CANADIAN BLOOD SERVICES
    Inventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
  • Patent number: 11001795
    Abstract: An in vitro microfluidic gut-on-chip is described herein that mimics the structure and at least one function of specific areas of the gastrointestinal system in vivo. In particular, a multicellular, layered, microfluidic culture is described, allowing for interactions between lamina propria-derived cells and gastrointestinal epithelial cells and endothelial cells. This in vitro microfluidic system can be used for modeling inflammatory gastrointestinal tissue, e.g., Crohn's disease, colitis and other inflammatory gastrointestinal disorders. These multicellular, layered microfluidic gut-on-chip further allow for comparisons between types of gastrointestinal tissues, e.g., small intestinal deuodejeum, small intestinal ileium, large intestinal colon, etc., and between disease states of gastrointestinal tissue, i.e. healthy, pre-disease and diseased areas.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 11, 2021
    Assignee: Emulate, Inc.
    Inventors: S. Jordan Kerns, Jenifer Obrigewitch, Michael Salmon, Magdalena Kasendra, Benjamin Richards Umiker
  • Patent number: 11000552
    Abstract: The purpose of the present invention is to provide a novel medicinal use in regeneration medicine, said medicinal use comprising using pluripotent stem cells (Muse cells). Provided is a cell preparation for treating skin ulcer, said cell preparation comprising SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue of a living organism or cultured mesenchymal cells. The cell preparation according to the present invention is based on such mechanism of skin tissue regeneration that, when the Muse cells are administered to a skin ulcer site of a subject suffering from the aforesaid disease, the Muse cells differentiate into skin-constituting cells.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: May 11, 2021
    Assignees: The University of Tokyo, Tohoku University
    Inventors: Kotaro Yoshimura, Kahori Kinoshita, Mari Dezawa
  • Patent number: 10988733
    Abstract: A method for obtaining a plurality of pluripotent adult olfactory stem cells (APOSCs) includes isolating the APOSCs, culturing the isolated APOSCs in a sphere culture medium, and collecting the cultured APOSCs that express Bmi-1 (B-lymphoma moloney murine leukemia virus insertion region-1), Oct-4 (Octamer-binding transcription factor 4), Sox-2 (Sex-determining region Y (SRY)-box 2), Nanog, SSEA-4 (Stage-specific embryonic antigen-4), ki67, c-Myc, KLF-4 (Kruppel Like Factor 4), K14 (Cytokeratin 14) and ICAM-1 (Intercellular Adhesion Molecule 1).
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: April 27, 2021
    Assignee: China Medical University
    Inventors: Woei-Cherng Shyu, Chung-Y. Hsu, Der-Yang Cho, Chen-Huan Lin, Wei Lee, San-Yuan Chen, Long-Bin Jeng, Chang-Hai Tsai
  • Patent number: 10987428
    Abstract: Provided herein are, inter alia, nucleic acid conjugates including a non-cell penetrating ribonucleic acid compound attached at its 3? end to a phosphorothioate polymer. Attachment of the phosphorothioate polymer to the non-cell penetrating ribonucleic acid conveys stability to and allows for efficient intracellular delivery of the non-cell penetrating ribonucleic acid. The nucleic acid conjugates provided herein including embodiments thereof are useful, inter alia, for the treatment of cancer, inflammatory disease, and pain.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: April 27, 2021
    Assignee: CITY OF HOPE
    Inventors: Andreas Herrmann, Hua Yu
  • Patent number: 10988777
    Abstract: The present invention relates to a new method for successfully inducing the mutation of cell chemokine receptor CCR5 gene into CCR5?32 deletion gene by using the CRISPR-Cas9 genome editing technique. CCR5 is an important co-receptor for entry of Human Immunodeficiency Virus (HIV) into human host cells. CCR5?32 deletion is a 32-bp deletion in CCR5 coding region, which results in change and premature termination in the sequence following the 185th amino acid. Biallelic homozygous deletion of CCR5?32 is naturally resistant to HIV infection, i.e., the people carrying this mutation can't be infected by HIV. The present invention uses both lentiviral packaging system and the CRISPR technique to induce CCR5?32 deletion. Due to the characteristics of a wide range of Lentivirus infection, the invention can be applied to cells such as bone marrow stem cells and CD4+ T cells and can be expected to be the therapeutic drug for HIV/AIDS infection or other diseases.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: April 27, 2021
    Assignee: Nankai University
    Inventors: Min Wei, Chunxia Qi
  • Patent number: 10982188
    Abstract: The invention provides a method of producing a synthetic retina, comprising: i) providing a three dimensional stem cell culture throughout the differentiation time course, ii) differentiating the three dimensional stem cell culture for a first time period in a first neural cell culture medium comprising: a) L-glutamine; b) B27 supplement; and c) an IGF-1 receptor agonist, iii) subsequently differentiating the three dimensional stem cell culture for a second time period in a second neural cell culture medium comprising: a) L-glutamine; b) B27 supplement; c) N2 supplement; and d) an IGF-1 receptor agonist, wherein said synthetic retina contains laminated retinal tissue comprising.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: April 20, 2021
    Assignee: Newcells Biotech Limited
    Inventors: Majlinda Lako, Carla Mellough
  • Patent number: 10975355
    Abstract: Methods are provided for the simple, fast, effective and safe directed differentiation of embryonic stem cells into pancreatic beta-like cells secreting insulin in response to glucose levels. The cells are useful transplant therapeutics for diabetic individuals.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: April 13, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Matthias Hebrok, Holger Andreas Russ
  • Patent number: 10973854
    Abstract: The invention provides a method for producing a retinal tissue by (1) subjecting pluripotent stem cells to floating culture in a serum-free medium containing a substance inhibiting the Wnt signal pathway to form an aggregate of pluripotent stem cells, (2) subjecting the aggregate to floating culture in a serum-free medium containing a basement membrane preparation, and then (3) subjecting the aggregate to floating culture in a serum-containing medium. The invention also provides a method for producing an optic-cup-like structure, a method for producing a retinal pigment epithelium, and a method for producing a retinal layer-specific neural cell.
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: April 13, 2021
    Assignees: Sumitomo Chemical Company, Limited, RIKEN
    Inventors: Tokushige Nakano, Satoshi Ando, Yoshiki Sasai, Mototsugu Eiraku
  • Patent number: 10976308
    Abstract: The present invention relates a method for chemical testing, comprising culturing cells in a first plant-derived nanofibrillar cellulose (NFC) hydrogel to obtain in vivo like cells; exposing the in vivo like cells to a test chemical; optionally within another plant-derived NFC hydrogel; incubating the exposed in vivo like cells; detecting during or after incubating, the impact of the test chemical on the in vivo like cells by at least one detection; and removing the plant-derived NFC hydrogel at least once at any stage after obtaining the in vivo like cells and before at least one detection used for detecting the impact of the test chemical on the in vivo like cells. The invention further relates to the use of plant-derived NFC hydrogel in a method for chemical testing, the use of in vivo like cells obtained by culturing cells in plant-derived NFC hydrogel for chemical testing and to a kit for chemical testing comprising plant-derived NFC hydrogel, instructions and a cell or test chemical library.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: April 13, 2021
    Assignee: UPM-KYMMENE CORPORATION
    Inventors: Marjo Yliperttula, Arto Urtti, Yan-Ru Lou, Melina Malinen, Patrick Laurén, Liisa Kanninen, Kirsti Johanna Niklander, Petter Somersalo, Riina Harjumäki
  • Patent number: 10968427
    Abstract: A method of expanding and maintaining human embryonic stem cells (ESCs) in an undifferentiated state by culturing the ESCs in a suspension culture under culturing conditions devoid of substrate adherence is provided. Also provided are a method of deriving ESC lines in the suspension culture and methods of generating lineage-specific cells from ESCs which were expanded in the suspension culture of the present invention.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: April 6, 2021
    Assignee: Teehnion Research & Development Foundation Limited
    Inventors: Michal Amit, Joseph Itskovitz-Eldor
  • Patent number: 10967007
    Abstract: Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: April 6, 2021
    Assignee: University of Maryland, Baltimore
    Inventor: Sunjay Kaushal
  • Patent number: 10960025
    Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: March 30, 2021
    Assignee: Mesoblast International Sárl
    Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
  • Patent number: 10959997
    Abstract: The present invention provides an agent for treating or preventing a disease, a disorder or a condition of a corneal endothelium, said agent comprising a corneal endothelial cell and a myosin II-specific inhibitor. More specifically, the myosin II-specific inhibitor is blebbistatin. The disease, the disorder or the condition is typically a disorder associated with Fuchs endothelial corneal dystrophy or corneal endothelial dysfunction (bullous keratopathy). Also provided is a method for treating or preventing a corneal endothelial disease, said method comprising a step of administering an effective amount of a myosin II-specific inhibitor together with a corneal endothelial cell to a subject.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: March 30, 2021
    Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
  • Patent number: 10947501
    Abstract: The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: March 16, 2021
    Assignee: The Schepens Eye Research Institute
    Inventors: Michael J. Young, Budd A. Tucker, Petr Y. Baranov
  • Patent number: 10946119
    Abstract: The present invention relates to a biologically active medical device, which includes a matrix seeded with progenitor cells, and then covered by ciliated tissue. The matrix is capable of enabling cellular migration. The ciliated tissue is ependymal cells that express at least one of tight junctional complexes, zonula adherens, and gap junctions. The progenitor cells include subpendymal progenitor cells. In some cases the progenitor cells include stem cells, and the ciliated tissue includes at least one of Choroid cells, tanacytes, and circumventricular organs. In some embodiments, the medical device is oriented into a tubular structure in order to form a cerebrospinal shunt. Additional cells and structures may be imbedded within the matrix, such as glia, endothelial cells, stem cells, and blood vessels. The medical device may also be incorporated into a bioreactor including a flexible inner tube defining an anthropomorphically shaped lumen.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: March 16, 2021
    Inventor: Milan Radojicic
  • Patent number: 10947506
    Abstract: The present invention provides populations of human cardiovascular progenitor cells, methods of making such cells, and methods of using the cells for production of populations of cardiovascular colonies and populations of cardiomyocytes. Methods of cardiomyocytes replacement therapy are also provided.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: March 16, 2021
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Gordon M. Keller, Lei Yang, Steven Kattman
  • Patent number: 10940241
    Abstract: Methods are provided for promoting cartilage growth and/or repair. The methods include, administering locally to a site in a subject in need thereof, bone marrow stromal cells attached to fibrin microbeads comprising crosslinked hyaluronic acid and thereby producing stable cartilage locally at the site in the subject.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: March 9, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Hadasit Medical Research Services and Development Ltd.
    Inventors: Pamela Gehron Robey, Sergei Kuznetsov, Raphael Gorodetsky, Astar Hailu-Lazmi, Mitchell Shirvan, Joseph Featherall
  • Patent number: 10941383
    Abstract: An isolated human brown adipose tissue stem cell line. In one embodiment, the isolated human brown adipose tissue stem cell line expresses the markers CD9, SSEA4, CD44, CD90, CD166, CD73, but not CD14, CD34, CD45 or STRO-1. In another embodiment, the isolated human brown adipose tissue stem cell line expresses the genes UCP1, PPARGC1A, NRF1, FOXC2, CREB1, SIRT3, and WNT5A (REFX). In still another embodiment, the isolated human brown adipose tissue stem cell line is capable of differentiating into osteoblasts, chondrocytes, and adipocytes.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: March 9, 2021
    Assignee: BIORESTORATIVE THERAPIES, INC.
    Inventor: Francisco Javier Silva
  • Patent number: 10933124
    Abstract: A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, said anti-third party cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, wherein said cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: March 2, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Noga Or-Geva, Eran Ophir, Yaki Eidelstein, Rotem Gidron Budovsky
  • Patent number: 10928382
    Abstract: A microfluidic device provides high throughput generation and analysis of defined three-dimensional cell spheroids with controlled geometry, size, and cell composition. The cell spheroids of the invention mimic tumor microenvironments, including pathophysiological gradients, cell composition, and heterogeneity of the tumor mass mimicking the resistance to drug penetration providing more realistic drug response. The device is used to test the effects of antitumor agents.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: February 23, 2021
    Assignee: Northeastern University
    Inventors: Tania Konry, Noa Cohen, Pooja Sabhachandani
  • Patent number: 10925999
    Abstract: The present invention provides, among other things, a elastomeric biomaterial having enzymatically cross-linked amino acid phenolic side chains to generate highly elastic hydrogels. Materials are characterized by tunable mechanical properties, gelation kinetics and swelling properties of these new protein polymers. Provided materials are support encapsulation of cells. Methods of making and using of provided particles are also disclosed.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: February 23, 2021
    Assignee: Trustees of Tufts College
    Inventors: Craig W. Hanna, Benjamin P. Partlow, David L. Kaplan
  • Patent number: 10918672
    Abstract: A method of curing (or at least treating) HIV, by obtaining small tissue mesenchymal stem cells (stMSC) from adipose tissue of a patient with HIV or from a syngeneic donor or an immuno-compatible donor, wherein said stMSC are i) 4-6 ?m in diameter, ii) pluripotent, and iii) have CD11b?, CD34?, CD45?, CD 29, CD 49, Oct 4 and SSEA 4 surface markers when harvested. Preferred sources are autologous adipose tissue. Next those stMSCs are gene edited to provide CCR5? stMSCs and optionally amplified by growth in culture and/or by cell selection for gene edited stMSCs and then re-introducing into the patient. Preferably, the CCR5? stMSCs will re-populate the patient with stem cells that can no longer act as latent HIV reservoirs and can differentiate into immune cells that are HIV resistant. If desired, the patient can be first treated, e.g., by radiation, to destroy the bone marrow cells before the re-introduction.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: February 16, 2021
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Stephen E. Braun, Reza Izadpanah, Eckhard Alt
  • Patent number: 10920197
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: February 16, 2021
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen Joseph Elliman
  • Patent number: 10920194
    Abstract: Hair follicle bulge region/LLP region CD34(+) MeSCs can be isolated from mammalian skin bearing hair follicles. These cells are multipotent and retain the ability to differentiate into cells of neural crest lineage, including glia-like cells that express the glial marker Gfap, and are able to express myelin basic protein, and to remyelinate naked (unmyelinated or demyelinated) neuronal processes with a functional, dense myelin sheath. These cells of neural crest lineage can be used to produce a dense myelin sheath on neurons which lack myelin due to genetic defect, trauma, toxin, infection, or disease process. Therefore, embodiments of the invention provide methods for preparing such cells, the cells themselves and compositions containing the cells, as well as methods for using the cells.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: February 16, 2021
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Thomas Hornyak, Sandeep Joshi
  • Patent number: 10907131
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: February 2, 2021
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen Joseph Elliman
  • Patent number: 10906976
    Abstract: The present invention provides for a novel method for inhibiting an undesirable immune response, especially in transplant recipients such as those having received an allogeneic stem cell transplant. Also disclosed are related compositions and kits for inducing immunotolerance.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: February 2, 2021
    Assignee: The Chinese University of Hong Kong
    Inventors: Oi Lan Kathy Lui, Herman Waldmann
  • Patent number: 10906187
    Abstract: An unmanned ground vehicle includes a main body, a drive system supported by the main body, and a manipulator arm pivotally coupled to the main body. The drive system comprising right and left driven track assemblies mounted on right and left sides of the main body. The manipulator arm includes a gripper, a wrist motor configured for rotating the gripper, and an inline camera in a palm of the gripper. The inline camera is mechanically configured to remain stationary with respect to the manipulator arm while the wrist motor rotates the gripper.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: February 2, 2021
    Assignee: FLIR DETECTION, INC.
    Inventors: Annan Michael Mozeika, Timothy R. Ohm, Christopher Thomas Brown
  • Patent number: 10894895
    Abstract: The present invention provides a two-component bioink including a first solution and a second solution separately, wherein (i) the first solution includes a first biopolymer to which a first chemical functional group is introduced, and the second solution includes a second biopolymer to which a second chemical functional group able to chemically bond with the first chemical functional group is introduced; or (ii) the first solution includes a third biopolymer having a first electrostatic functional group, and the second solution includes a fourth biopolymer having a second electrostatic functional group able to physically bond with the first electrostatic functional group, a 3D biomaterial including the same, and a method for preparing the same.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: January 19, 2021
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Kyung Sook Kim, Da Yeon Kim, Seung Hun Park, Ja Yong Jang, Moon Suk Kim
  • Patent number: 10888588
    Abstract: Disclosed is a fully chemically defined, small molecule-mediated, directed differentiation system that promotes differentiation of stem cells, including embryonic stem cells, induced pluripotent stem cells, and adult stem cells, such as human forms of these stem cell types, to ventricular cardiomyocytes in a highly efficient, reproducible and scalable fashion. Also disclosed is a cost-effective and efficient protocol, or method, for generating cardiomyocytes and a cost-effective and efficient method of maturing cardiomyocytes. The disclosed differentiation system provides a platform to perform large-scale pharmacological screenings and to provide a valuable source of each of cardiac progenitor cells and cardiomyocytes for cell replacement therapies in cardiac repair.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: January 12, 2021
    Assignees: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, THE UNIVERSITY OF HONG KONG
    Inventors: Roger Joseph Hajjar, Camie W. Chan
  • Patent number: 10881693
    Abstract: The present application provides methods and processes for making and using a mesenchymal stem cell secretome, as well as methods for treating ocular conditions and/disorders with the mesenchymal stem cell secretome described herein.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: January 5, 2021
    Assignee: COMBANGIO, INC.
    Inventor: Spencer Alford
  • Patent number: 10882891
    Abstract: The present invention contemplates dendritic cell compositions. The dentritic cell compositions employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC II presentation of the antigen or fragment thereof. In particular, the invention refers to a dendritic cell vaccine comprising dendritic cells expressing a MHC class-II targeting signal fused to an antigen or fragment thereof. Dendritic cell vaccines for the stimulation of an immune response against melanoma-associated antigen are also described.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: January 5, 2021
    Assignees: MEDIGENE IMMUNOTHERAPIES GMBH, HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)
    Inventors: Slavoljub Milosevic, Christian Ellinger, Carina Wehner, Dolores Schendel
  • Patent number: 10869900
    Abstract: The present invention relates to in vitro cultured senescent cells, such as epithelial cells, keratinocytes and/or fibroblasts as well as their use in the treatment of tissue regeneration, particularly for the treatment of wounds such as burns or ulcers or the treatment of inflammatory conditions. Optionally, products may be used in combination with further drugs including antimicrobial or antidiabetic agents.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: December 22, 2020
    Assignee: QRSkin GmbH
    Inventor: Martin Funk
  • Patent number: 10870783
    Abstract: Provided herein is a surfactant adhesive protein comprising an amphiphilic peptide at the carbon or amine terminal of the protein, enabling homogeneous dispersion of several materials in various solvents and coating of the homogeneously dispersed particles on a hydrophilic or hydrophobic surface, particularly the homogeneous dispersion of hydrophilic or hydrophobic particles in a hydrophobic or hydrophilic solvent on the basis of strong adhesive strength of a mussel adhesive protein; the surface adhesive protein can be used as a surface coating agent requiring antibacterial or antiviral functions as well as a cosmetic product or an ink.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: December 22, 2020
    Assignee: KOLLODIS BIOSCIENCES, INC.
    Inventors: Sang Jae Lee, Bong Jin Hong
  • Patent number: 10865385
    Abstract: The present invention discloses a method of isolation, pooling and further culturing of Mesenchymal Stem cells (MSC) for clinical application. Present invention also discloses the method of establishing Master Cell bank, followed by Working Cell Bank from which the final therapeutic composition referred to as Investigational Product/Investigational Medicinal Product comprising of allogenic bone marrow-derived MSC is formulated for clinical applications.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: December 15, 2020
    Assignee: Stempeutics Research Pvt. Ltd.
    Inventors: Rakhi Pal, Pawan Kumar Gupta, Prasanna Kumar Kemburu, Jyothi Prasanna, Satish Totey, Raviraja Neelavar Seetharam, Umesh Baikunje Golithadka, Anish Sen Majumdar
  • Patent number: 10857264
    Abstract: Biomaterial having a multi-dimensional structure and comprising demineralized bone matrix dispersed within differentiated mesenchymal stem cells (MSCs) tissue, wherein MSCs are adipose tissue-derived stem cells. Method for producing this biomaterial comprising incubating MSCS in osteoblastic and/or chondrongenic medium in presence of demineralized bone matrix. Use of this biomaterial for alleviating or treating a bone or cartilage defect, supporting or correcting a congenital or acquired abnormality, supporting a bon or articular bone replacement following surgery or trauma, and/or supporting a musculoskeletal implant.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: December 8, 2020
    Assignees: Universite Catholique De Louvain, Cliniques Universitaires Saint-Luc
    Inventors: Denis Dufrane, Christian Delloye
  • Patent number: 10858627
    Abstract: Disclosed is a method to differentiate stern, progenitor or precursor cells comprising contacting said stem, progenitor or precursor cells with miR-130a, or an RNA having at least 95% identity thereto, so as to yield cells of endothelial lineage. Further disclosed are compositions comprising the endothelial lineage cells obtained and methods of using the compositions for treating diseases including cardiovascular diseases.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: December 8, 2020
    Assignee: Regents of the University of Minnesota
    Inventors: Daniel J. Garry, Naoko Koyano-Nakagawa, Mary G. Garry, Bhairab Singh
  • Patent number: 10851366
    Abstract: The present invention relates to novel peptides derived from Lengsin (LGSN), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: December 1, 2020
    Assignee: IMMUNOCORE LIMITED
    Inventors: Alex Powlesland, Maurits Kleijnen
  • Patent number: 10851345
    Abstract: Methods and products obtained from the method for isolating and culturing mixed populations of stem cells, making decellularized tissue matrix, making decellularized tissue matrix infused with said mixed populations of stem cells, and methods of stem cell therapy are provided.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: December 1, 2020
    Assignee: Stem Cell Reserve LP
    Inventor: Raymond Mouzannar
  • Patent number: 10850007
    Abstract: A method of producing a modified acellular tissue matrix (mATM) from an acellular tissue matrix (ATM), where the mATM has a reduced stretchiness relative to the ATM, without substantially compromising its associated structural or functional integrity. The method includes providing an acellular tissue matrix (ATM) and exposing the ATM to elastase for a period of time.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: December 1, 2020
    Assignee: LifeCell Corporation
    Inventor: Wendell Sun
  • Patent number: 10835558
    Abstract: The present disclosure generally relates to constructs, formulations and methods for the treatment of various types of cancer. The constructs, formulations and methods as provided herein are particularly useful for the treatment of various tumorigenic cancers.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: November 17, 2020
    Assignee: Brahm Holdings, Inc.
    Inventor: Timothy R. Brahm